| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Analysts' ratings for Encompass Health (NYSE:EHC) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $145.0, a high estimate of $160.00, and a low estimate of $140.00. Witnessing a positive shift, the current average has risen by 6.42% from the previous average price target of $136.25.
The perception of Encompass Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matthew Gillmor | Keybanc | Raises | Overweight | $140.00 | $135.00 |
| Kevin Fischbeck | B of A Securities | Raises | Buy | $160.00 | $145.00 |
| David Macdonald | Truist Securities | Raises | Buy | $140.00 | $135.00 |
| Andrew Mok | UBS | Raises | Buy | $140.00 | $130.00 |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Encompass Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Encompass Health analyst ratings.
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Encompass Health's revenue growth over a period of 3M has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 12.03%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Encompass Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.75% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Encompass Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Encompass Health's ROA excels beyond industry benchmarks, reaching 2.12%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.18.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: EHC
